Nina S Kjellson sold $410k of TYRA
director at Tyra Biosciences, Inc.. 25,041 shares at an average of $16.36, traded Jan 16, 2025, filed Jan 21, 2025.
Score components
- +15RoleDirector
- +16Trade size$410k at market
- 0Share of holdings soldSold 0.7% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-007426, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 16, 2025 | SOpen-market sale Common Stockindirect: By Canaan XI L.P. | -6,944 | $16.29 | $113k | 3,724,221 | Jan 21, 2025 |
| Jan 16, 2025 | SOpen-market sale Common Stockindirect: By 2020+ Co-Investment L.P. - Series 7 | -835 | $16.29 | $14k | 447,857 | Jan 21, 2025 |
| Jan 17, 2025 | SOpen-market sale Common Stockindirect: By Canaan XI L.P. | -12,808 | $16.40 | $210k | 3,711,413 | Jan 21, 2025 |
| Jan 17, 2025 | SOpen-market sale Common Stockindirect: By 2020+ Co-Investment L.P. - Series 7 | -461 | $16.40 | $7,560 | 447,396 | Jan 21, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Canaan XI L.P | -3,993 | $16.36 | $65k | 3,707,420 | Jan 21, 2025 |
Related signals
Other insiders at Tyra Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TYRAbuy Tyra Biosciences, Inc. | Rehan Verjee director | $20k 972 shares | - | |
| 23Weak | TYRAsell Tyra Biosciences, Inc. | Nina S Kjellson director | $74k 5,401 shares | -0% | |
| 24Weak | TYRAsell Tyra Biosciences, Inc. | Nina S Kjellson director | $78k 4,825 shares | -0% | |
| 24Weak | TYRAsell Tyra Biosciences, Inc. | Nina S Kjellson director | $89k 5,272 shares | -0% | |
| 51Moderate | Tyra Biosciences, Inc. | Ra Capital Management, L.p. director, owner | $20M 1,220,681 shares | +16% | |
| 40Moderate | TYRAsell Tyra Biosciences, Inc. | Nina S Kjellson director | $1.3M 74,582 shares | -2% | |
| 27Weak | TYRAsell Tyra Biosciences, Inc. | Nina S Kjellson director | $194k 11,569 shares | -0% | |
| 51Moderate | Tyra Biosciences, Inc. | Alan Fuhrman Chief Financial Officer | $152k 9,500 shares | +284% | |
| 48Moderate | Tyra Biosciences, Inc. | Nina S Kjellson director | $2.3M 138,711 shares | -4% | |
| 38Weak | Tyra Biosciences, Inc. | Todd Harris President and CEO | $1.7M 62,720 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.